ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2019
Monitoring the heart during cancer therapy.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- Cardiovascular Mortality Risk Among Patients with Liver Cancer: A SEER Database Study.Current cancer drug targets · 2025Article
- Mitral Annular Plane Systolic Excursion (MAPSE): A Review of a Simple and Forgotten Parameter for Assessing Left Ventricle Function.Journal of clinical medicine · 2024Review
- Breast Cancer and Therapy-Related Cardiovascular Toxicity.Journal of breast cancer · 2024Review
- Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.Journal of ovarian research · 2024Article
- Histopathological and epigenetic changes in myocardium associated with cancer therapy-related cardiac dysfunction.ESC heart failure · 2022Article
- Detection of Anticancer Drug-Induced Cardiotoxicity Using VCAM1-Targeted Nanoprobes.ACS applied materials & interfaces · 2022Article
- Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study.Journal of cardiovascular development and disease · 2022Article
- Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer.International journal of molecular sciences · 2022Review
- Personalizing Heart Failure Care to the Patient With Cancer.Current heart failure reports · 2022Review
- Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.Children (Basel, Switzerland) · 2021Review
- Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.Cancer medicine · 2021Article
- Review
- Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing number of effective cancer therapies is associated with cardiovascular (CV) toxicities including myocardial injury or dysfunction, leading to reduced ventricular function, and increased risk of heart failure. As the timing of administration of cancer treatment is known, the potential for risk stratification pre-treatment, and appropriate surveillance and monitoring during treatment, and intervention with cardio-protective treatment strategies in patients exhibiting early evidence of CV toxicity is an appealing clinical strategy. The field of cardio-oncology has developed, and the application of monitoring strategies using CV biomarkers and CV imaging has been to focus of many studies and is now implemented in dedicated cardio-oncology services supporting oncology centres. In this article, we review the background and rationale for monitoring, the different options and their strengths, weaknesses and where they are helpful in specific cardiotoxic cancer therapies, and the impact in cardio-oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.